Year: 2024

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

Written by Customer Service on November 20, 2024. Posted in Mergers And Acquisitions.

Additions of ProgenaMatrix® and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolio POMPANO BEACH, Fla., Nov. 20, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today announced the signing of a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare Global LLC (“ProgenaCare”), a pioneering medical device company leveraging cutting-edge advances in biomaterials to provide effective, affordable advanced wound care solutions. The acquisition of ProgenaMatrix and revyve Antimicrobial Wound Gel reflects the Company’s continued commitment to building a diverse portfolio of complementary wound care...

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Written by Customer Service on November 20, 2024. Posted in Mergers And Acquisitions.

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discovery Recursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and YoutubeSALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) — The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform....

LuxUrban Hotels Inc. Reports Third Quarter 2024 Financial Results

Written by Customer Service on November 20, 2024. Posted in Earnings Releases And Operating Results.

MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) — LuxUrban Hotels Inc. (Nasdaq: LUXH), a hospitality company that leases entire hotels on a long-term basis, manages these hotels, and rents out rooms to guests in the properties it leases, today announced its financial results for the third quarter ended September 30, 2024 (“Q3 2024”). The Company filed its quarterly report on Form 10-Q for Q3 2024 with the U.S. Securities and Exchange Commission on November 19, 2024. Q3 2024 Financial Overview:Net Rental Revenue: $13.1 million, compared to $31.2 million in Q3 2023. Gross (Loss) Profit: $(16.8) million, compared to a profit of $7.8 million in Q3 2023, impacted by [brief explanation of factors affecting performance]. We have streamlined our hotel portfolio to exclude underperforming properties and now manage eight (8) hotels with a total...

Global-e Reports Third Quarter 2024 Results

Written by Customer Service on November 20, 2024. Posted in Earnings Releases And Operating Results.

PETAH-TIKVA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) — Global-e Online Ltd. (Nasdaq: GLBE) the leader of global Direct-To-Consumer eCommerce enablement, today reported financial results for the third quarter of 2024. “We report today the results of another very strong quarter, with growth of GMV accelerating to 35% year over year and many new merchants going live ahead of the holiday season, including the iconic luxury department store Harrods,” said Amir Schlachet, Founder and CEO of Global-e. “Given the successful merchant launches in the recent months, combined with our new bookings for this year which are at an all-time high, we believe that this strong growth momentum will continue.” Q3 2024 Financial ResultsGMV1 in the third quarter of 2024 was $1,134 million, an increase of 35% year over year Revenue in the third quarter...

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Written by Customer Service on November 20, 2024. Posted in Earnings Releases And Operating Results.

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, with Data Expected in Mid-2025 Well-Capitalized with Balance Sheet to Support a Planned Operating Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) — Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today reported financial results for the third quarter ended September 30, 2024 and provided a portfolio overview and business highlights. “At Septerna, we recently celebrated two major milestones: our transition to a clinical-stage company with the initiation of our Phase 1 clinical...

Mawson Infrastructure Group Inc. Announces Monthly Operational Update for October 2024

Written by Customer Service on November 20, 2024. Posted in Public Companies.

Total Monthly Revenue grew 49% Y/Y from October 2023 and is up 18% M/M from September 2024 Digital Colocation Monthly Revenue grew 18% M/M from September 2024 Digital Assets Mining Monthly Revenue grew 25% M/M from September 2024 MIDLAND, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) — Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson” or “the Company”), a publicly-traded technology company focused on digital infrastructure platforms for artificial intelligence (AI), high-performance computing (HPC), and digital assets markets, today announced its unaudited business and operational update for October 2024. Rahul Mewawalla, CEO and President said, “We are pleased to deliver another month of strong growth across our business with our total monthly revenue increasing 49% year-over-year and 18% month-over-month. We continue to advance...

HydroGraph Receives Purchase Order for Four Novel Graphenes from Global Automotive Customer

Written by Customer Service on November 20, 2024. Posted in Public Companies.

Commercial Expansion Prompts HydroGraph to Appoint Darrow Associates for Investor Relations TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) — HydroGraph Clean Power Inc. (CSE: HG) (OTCQB: HGRAF) (FRA: M98) (the “Company” or “HydroGraph”), a sustainable commercial manufacturer of pristine graphene, announced today that it has received a purchase order from a major global automotive company for research quantities of four additional graphene products. The purchase order includes both pristine functionalizations and completely novel formulations produced by HydroGraph’s patented explosion synthesis process. The new purchase order, dated on November 18 and received by HydroGraph on November 19, is an expansion of the ongoing automotive composite improvement program which began with the customer earlier in 2024, adding new graphene projects...

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation

Written by Customer Service on November 20, 2024. Posted in Public Companies.

SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic and phenotypic data from the 23andMe research database and its proprietary Mirador360™ development engine to enable target validation and precision medicine. The 23andMe genetic and phenotypic health information database is the world’s largest crowdsourced platform for genetic research. Insights gleaned from the 23andMe database...

Ollie’s Bargain Outlet Holdings, Inc. Announces Third Quarter Fiscal 2024 Release Date and Conference Call Information

Written by Customer Service on November 20, 2024. Posted in Public Companies.

HARRISBURG, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) announced today that it will release its financial results for the third quarter of fiscal year 2024 on Tuesday, December 10, 2024, before the market opens. Following the release, at 8:30 a.m. Eastern Time, the Company’s management team will host a conference call to discuss its results. To access the live conference call, please pre-register here. Registrants will receive a confirmation with dial-in instructions. Interested parties can also listen to a live webcast or replay of the conference call by logging on to the Investor Relations section on the Company’s website at https://investors.ollies.us/. About Ollie’sWe are America’s largest retailer of closeout merchandise and excess inventory, offering Real Brands...

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Written by Customer Service on November 20, 2024. Posted in Public Companies.

TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populations Study execution update is expected during ASH 2024SAN DIEGO and TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced initiation of the TUSCANY study, tuspetinib (TUS) in combination therapy with azacitidine (AZA) and venetoclax (VEN) as a frontline triplet combination therapy for patients newly diagnosed with acute myeloid leukemia, or AML. The trial is being conducted...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals